Staff Members - Benha University
Urinary Soluble Alpha Chain of the Interleukin-2 Receptor as a Biomarker of Active Lupus Nephritis in Egyptian Children With Juvenile Systemic Lupus Erythematosus
Archives of rheumatology • 2021
Publication Information
Authors
Waleed HASSAN1, Eman BEHIRY2, Marwa MAHGOUB1
Keywords
Not Available
Journal
Archives of rheumatology
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
International
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
BSTRACT
Objectives: This study aims to assess the urinary soluble alpha chain of the interleukin-2 receptor (sCD25) concentrations in patients with juvenile
systemic lupus erythematosus (JSLE) and to evaluate its validity to be a possible marker of disease activity in patients with lupus nephritis (LN).
Patients and methods: We assessed sCD25 concentrations in urine samples obtained from 53 JSLE patients (15 males, 38 females; median age
11 years; range, 7 to 17 years) and 30 age- and sex-matched apparently healthy controls (10 males, 20 females; median age 10 years; range, 6 to
16 years). Concentrations were normalized according to urinary creatinine excretion. JSLE patients were subjected to clinical examination and
assessment of overall disease activity by Systemic Lupus Erythematous Disease Activity Index (SLEDAI), while evaluation of LN activity was preformed
using Systemic Lupus International Collaborating Clinics (SLICC) renal activity score.
Results: The JSLE patients had significantly higher normalized urinary sCD25 concentrations compared to the healthy controls (p=0.001). Patients
with active LN had significantly higher normalized urinary sCD25 levels than active JSLE patients without LN (p=0.002) and JSLE patients with
inactive disease (p
Objectives: This study aims to assess the urinary soluble alpha chain of the interleukin-2 receptor (sCD25) concentrations in patients with juvenile
systemic lupus erythematosus (JSLE) and to evaluate its validity to be a possible marker of disease activity in patients with lupus nephritis (LN).
Patients and methods: We assessed sCD25 concentrations in urine samples obtained from 53 JSLE patients (15 males, 38 females; median age
11 years; range, 7 to 17 years) and 30 age- and sex-matched apparently healthy controls (10 males, 20 females; median age 10 years; range, 6 to
16 years). Concentrations were normalized according to urinary creatinine excretion. JSLE patients were subjected to clinical examination and
assessment of overall disease activity by Systemic Lupus Erythematous Disease Activity Index (SLEDAI), while evaluation of LN activity was preformed
using Systemic Lupus International Collaborating Clinics (SLICC) renal activity score.
Results: The JSLE patients had significantly higher normalized urinary sCD25 concentrations compared to the healthy controls (p=0.001). Patients
with active LN had significantly higher normalized urinary sCD25 levels than active JSLE patients without LN (p=0.002) and JSLE patients with
inactive disease (p